VANCOUVER, BC & MACQUARIE PARK, AUSTRAILIA-Contextual Genomics Inc., developers of molecular-based cancer tests, is partnering with medical diagnostic service provider Sonic Healthcare Limited to offer Next Generation Sequencing (NGS)-based genetic testing to cancer patients in Australia and other parts of the world.
Under the terms of the distribution, license and services agreement, Sonic will offer Find-It™, a molecular test for solid tumour cancers, at its laboratories to patients diagnosed with cancer. The Find-It™ hotspot assay screens for known gene mutations found in solid tumour cancers, most of which are treatable with current therapies or Phase 3 investigational treatments. Additionally, Sonic will have access to Contextual’s proprietary bioinformatics molecular analysis technology and quality control systems (QA Nexus™ suite) and Contextual will have access to Sonic’s federated structure of medically-led practices.
“Knowledge gained from molecular analysis allows patients and their oncologists to make informed, timely treatment decisions,” said Dr. David Huntsman, Contextual Genomics’ chief medical officer.
He adds that there are a growing number of new mutation-targeted cancer treatments only accessible through DNA-based testing, which has not been widely available. “Sonic’s global presence will broaden access to quality DNA-based diagnostics. This timely access to DNA diagnostics can lead to better outcomes for patients diagnosed with cancer,” he explains.
The Find-It™ cancer panel is a multiplex, next-generation sequencing genomic assay designed for rapid deployment into labs around the world. Find-It™ evaluates the mutation status of tumor DNA at more than 100 well-characterized positions, identifying the somatic mutations that have the greatest potential to impact treatment decisions. QA Nexus™ is a quality control system embedded into all Find-It™ assays and into Contextual’s bioinformatic pipeline.